Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

Hunan Province Tumor Hospital

Status: Enrolling

Conditions: Extensive-stage Small-cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT05991180

BELIEVE RWS

Details and patient eligibility

About

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Enrollment: 160 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must be ≥18 years.
• Provision of fully informed consent prior to any study specific procedures.
• Patients with extensive stage SCLC diagnosed by pathology (as staged by the American Veterans Lung Cancer Association (VALG)), who do not have an imaging response during first-line treatment with PD-(L)1 inhibitors, or who progress after imaging reactions on first-line therapy (the most recent regimen prior to enrollment must contain PD-(L)1 inhibitors).
• According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion criteria

• None